Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide

Key facts

Active substance
  • Olmesartan medoxomil
  • Amlodipine besilate
  • hydrochlorothiazide
Therapeutic area
Cardiovascular diseases
Decision number
P/226/2009
PIP number
Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Essential hypertension
Route(s) of administration
Oral use
Contact for public enquiries
Daiichi Sankyo Europe GmbH

E-mail: service@daiichi-sankyo.eu
Country: Germany
Phone: +49 8978080
Fax: +49 897808267

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Topics

How useful was this page?

Add your rating